Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ: LEGN )

36.42 +0.03 (+0.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Biotech Stocks That Analysts Are Drooling Over
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
From Legend Biotech Corporation
Via Business Wire
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast
Via Benzinga
Expert Ratings for Legend Biotech
Via Benzinga
Analyst's Verdict on Legend Biotech: Doubts On Commercial Execution, Long- Term Market Share
Via Benzinga
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Via Benzinga
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conference
From Legend Biotech Corporation
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
From Legend Biotech Corporation
Via Business Wire
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?
Legend's cell therapy seems like it's a winner, but it might be priced in already. 
Via The Motley Fool
Potential Breakout Setups To Watch On Wednesday
The U.S. stock market has weakened throughout Tuesday’s trading session and the major indices were sitting near session lows heading into the closing bell. 
Via Benzinga
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Legend Bio Hits Profit-Taking Zone After Reportedly Confirming Key Study Results
Legend Bio is on a run on excitement for its multiple myeloma treatment. 
Via Investor's Business Daily
Why Shares of Geron Are Up 30% This Week
The company's CEO was scheduled to speak at a virtual conference on Thursday. 
Via The Motley Fool
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.